International Journal of Stem Cells : eISSN 2005-5447

Table. 1.

Table. 1.

Demographic details, clinical characteristics, visual acuity and visual field results of the treated eyes with stem cells and the untreated fellow eyes at baseline and at 1 year follow-up

Subject No. Age/sex/disease Disease/study eye BCVA baseline (logMAR) BCVA 1 year (logMAR) MD (dB) (Baseline) MD (dB) (1 year)
1 19/F/SMD OD (Fellow eye) +0.60 +0.70 15.5 23.7
OS(Study eye) +1.3 +1.0 23.1 21.7
2 24/M/SMD OD (Study eye) +1.3 +1.3 12.0 9.6
OS(Fellow eye) +1.3 +1.6 13.3 14.7
3 20/M/SMD OD (Study eye) +2.0 +1.5 28.1 28.6
OS(Fellow eye) +1.6 +2.0 27.7 28.5
4 31/F/SMD OD (Fellow eye) +1.5 +1.6 18.9 21.9
OS(Study eye) +1.5 +1.0 21.6 19.1
5 75/M/AMD OD (Fellow eye) +1.0 +1.3 6.5 10.6
OS(Study eye) +1.8 +1.3 9.6 9.7
6 70/F/AMD OD (Fellow eye) +0.0 +0.0 25.7 26.1
OS(Study eye) +2.0 +1.3 24.5 20.2
7 60/M/AMD OD (Study eye) +1.8 +1.3 6.4 6.2
OS(Fellow eye) +0.40 +0.60 4.5 4.8
8 59/M/AMD OD (Study eye) +2.0 +1.3 18.5 17.9
OS(Fellow eye) +0.70 +1.0 7.3 8.6

AMD: Age related macular degeneration, BCVA: Best corrected visual acuity, logMAR: Logarithm of the minimum angle of resolution units OD: Oculus dexter, OS: Oculus sinister, SMD: Stargardts’ macular dystrophy, MD: Mean deviation dB: Decibel.

The numbers written in italics belong to the patients who experienced decrease during the follow-up period.

International Journal of Stem Cells 2021;14:47-57 https://doi.org/10.15283/ijsc20025
© 2020 International Journal of Stem Cells